Advances in Therapy
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis
By Denise Aysel Yardley, Shinzaburo Noguchi, Kathleen I. Pritchard, Show 16 more authorsHope S. Rugo
Randomised trial in peopleInterventions
Double-blind, placebo-controlled, registered NCT00863655
- Everolimus
- Everolimus + exemestane
- Hormone-receptor-positive advanced breast cancer
- Visceral metastases
- Humans
The paper
Sarah Cannon Research Institute; University of California, San Francisco
Advances in Therapy, 25 Oct 2013
